Isoray Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Isoray in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Isoray stock.
View analyst ratings for Isoray or view top-rated stocks.

Wall Street analysts have given Isoray a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Isoray wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Isoray is scheduled to release its next quarterly earnings announcement on Thursday, September 16th 2021.
View our earnings forecast for Isoray.

Isoray, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings results on Thursday, May, 13th. The healthcare company reported ($0.01) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The healthcare company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $2.44 million. Isoray had a negative net margin of 36.52% and a negative trailing twelve-month return on equity of 15.33%.
View Isoray's earnings history.

Isoray's stock was trading at $0.6706 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ISR shares have increased by 0.8% and is now trading at $0.6761.
View which stocks have been most impacted by COVID-19.

4 brokers have issued 1 year price targets for Isoray's stock. Their forecasts range from $1.00 to $3.00. On average, they anticipate Isoray's stock price to reach $2.03 in the next twelve months. This suggests a possible upside of 200.7% from the stock's current price.
View analysts' price targets for Isoray or view top-rated stocks among Wall Street analysts.

Some companies that are related to Isoray include iCAD (ICAD), Accuray (ARAY), TransEnterix (TRXC), Utah Medical Products (UTMD), Cytosorbents (CTSO), Apyx Medical (APYX), Co-Diagnostics (CODX), Profound Medical (PROF), The Westaim (WEDXF), Apollo Endosurgery (APEN), DarioHealth (DRIO), TELA Bio (TELA), Neuronetics (STIM), Beyond Air (XAIR) and Titan Medical (TMDI).
View all of ISR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."

Shares of ISR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISR stock can currently be purchased for approximately $0.68.

Isoray has a market capitalization of $95.64 million and generates $9.68 million in revenue each year. The healthcare company earns $-3,450,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

Isoray employs 53 workers across the globe.

The official website for Isoray is isoray.com.

Isoray is headquartered at 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States.

Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The healthcare company can be reached via phone at (509) 375-1202 or via email at [email protected]